Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

AI could give cancer patients a head start against metastasis

NCT ID NCT07616011

First seen Jun 07, 2026 · Last updated Jun 20, 2026 · Updated 4 times

Summary

This study will test an artificial intelligence system designed to predict when a cancer might spread to other parts of the body. Researchers will enroll 10,000 adults with malignant tumors but no current signs of metastasis. The AI analyzes routine imaging and medical records to spot subtle warning signs that human eyes might miss. If it works, doctors could intervene earlier, potentially reducing the number of patients whose cancer spreads.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MALIGNANT TUMOR WITH METASTASIS are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Artificial intelligence-based predictive model

What this could lead to

If successful, this AI tool could give doctors an early warning that cancer is about to spread, allowing earlier treatment and potentially better outcomes.

What could go wrong

This is an early-stage observational study, not a treatment trial. The AI model may not work as well in real-world settings as it did in past data, and it won't directly treat or cure cancer.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.